Oramed Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Oramed Pharmaceuticals heeft een totaal eigen vermogen van $155.5M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $165.1M en $9.6M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio	n/a
Contant	US$142.30m
Aandelen	US$155.52m
Totaal verplichtingen	US$9.56m
Totaal activa	US$165.08m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $142.8M ) OJU1 } overtreffen de korte termijn passiva ( $5.3M ).

Langlopende schulden: De kortetermijnactiva OJU1 ( $142.8M ) overtreffen de langetermijnschulden ( $4.3M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: OJU1 is schuldenvrij.

Schuld verminderen: OJU1 heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 0.2% was.

Schuldendekking: OJU1 heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: OJU1 heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Oramed Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

New major risk - Earnings quality

Investor sentiment deteriorates as stock falls 15%

New minor risk - Market cap size

Investor sentiment improves as stock rises 22%

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Investor sentiment improves as stock rises 17%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

New minor risk - Market cap size

Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: EPS: US$0.14 (vs US$0.94 loss in FY 2022)

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)

New major risk - Share price stability

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.03 loss per share (vs US$0.27 loss in 2Q 2022)

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

First quarter 2023 earnings released: US$0.085 loss per share (vs US$0.27 loss in 1Q 2022)

President recently bought €188k worth of stock

Independent Director recently bought €132k worth of stock

Full year 2022 earnings released: US$0.94 loss per share (vs US$0.94 loss in FY 2021)

Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)

Oramed Pharmaceuticals Inc. Reports Positive Top-Line Results from Phase 2 Nash Trial with its ORMD-0801, Oral Insulin Candidate

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 2Q 2021)

Oramed Reaches 50% Enrollment in Its Second Phase 3 Oral Insulin Trial

High number of new and inexperienced directors

Oramed Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2022

Oramed Pharmaceuticals Inc. Appoints Anne Peters to Its Scientific Advisory Board

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 1Q 2021)

Oramed Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study Ora-D-013-1

Oramed Pharmaceuticals Inc. Grants NASH Patent in Europe

Full year 2021 earnings released: US$0.94 loss per share (vs US$0.90 loss in FY 2020)

Independent Chairman of the Board recently sold €85k worth of stock

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral Covid-19 Vaccine Trial in South Africa

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oramed Pharmaceuticals Inc. Reaches 75% Enrollment in Phase 3 Oral Insulin Study

Independent Chairman of the Board recently sold €376k worth of stock

Independent Director Xiaoming Gao has left the company

Oramed Pharmaceuticals Inc. Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

Oramed Pharmaceuticals Inc. Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.098 loss in 3Q 2020)

CFO, Treasurer & Secretary Avraham Gabay has left the company

Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2020)

Oramed Pharmaceuticals Inc. Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

New 90-day high: €9.23

New 90-day high: €5.31

Oramed Pharmaceuticals Inc. Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

Revenue beats expectations

Revenue beats expectations

First quarter 2021 earnings released: US$0.23 loss per share

Oramed Pharmaceuticals Inc. Reports Positive First in Human Data from Oral Leptin Study

Oramed Pharmaceuticals Inc. Initiates Phase 2 NASH Trial of Oral Insulin

New 90-day high: €3.34

Revenue misses expectations

Oramed Pharmaceuticals Inc Initiates Phase 3 Trial of Oral Insulin

Full year 2020 earnings released: US$0.56 loss per share

New 90-day low: €2.13

New 90-day low: €2.32

New 90-day low - €2.90

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans